International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 65

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in *Cumulative List No. 13, 2009* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 65

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans la *Liste récapitulative No. 13, 2009* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 65

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran reunidas en *Cumulative List No. 13, 2009* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

amuvatinibum

amuvatinib — *N*-[(1,3-benzodioxol-5-yl)methyl]-4-([1]benzofuro[3,2-*d*]pyrimidin-4-yl)piperazine-1-carbothioamide

amuvatinib — *N*-[(1,3-benzodioxol-5-yl)méthyl]-4-([1]benzofuro[3,2-*d*]pyrimidin-4-yl)pipérazine-1-carbothioamide

amuvatinib — *N*-[(1,3-benzodioxol-5-il)metil]-4-([1]benzofuro[3,2-*d*]pirimidin-4-il)piperazina-1-carbotioamida

$C_{23}H_{21}N_5O_3S$



anagliptinum

anagliptin — *N*-[2-({2-[(2*S*)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-*a*]pyrimidine-6-carboxamide

anagliptine — *N*-[2-({2-[(2*S*)-2-cyanopyrrolidin-1-yl]-2-oxoéthyl}amino)-2-méthylpropyl]-2-méthylpyrazolo[1,5-*a*]pyrimidine-6-carboxamide

anagliptina — *N*-[2-({2-[(2*S*)-2-cianopirrolidin-1-il]-2-oxoetil}amino)-2-metilpropil]-2-metilpirazolo[1,5-*a*]pirimidina-6-carboxamida

$C_{19}H_{25}N_7O_2$



atecegatranum

atecegatran (2*S*)-*N*-[(4-carbamimidoylphenyl)methyl]-1-{(2*R*)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl}azetidine-2-carboxamide

atécégatran (2*S*)-*N*-[(4-carbamimidoylphényl)méthyl]-1-{(2*R*)-2-[3-chloro-5-(difluorométhoxy)phényl]-2-hydroxyacétyl}azétidine-2-carboxamide

atecegatrán (2*S*)-*N*-[(4-carbamimidoilfenil)metil]-1-{(2*R*)-2-[3-cloro-5-(difluorometoxi)fenil]-2-hidroxiacetil}azetidina-2-carboxamida

$C_{21}H_{21}ClF_2N_4O_4$



avibactamum

avibactam (1*R*,2*S*,5*R*)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

avibactam (1*R*,2*S*,5*R*)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

avibactam (1*R*,2*S*,5*R*)-7-oxo-6-sulfooxi-1,6-diazabiciclo[3.2.1]octano-2-carboxamida

$C_7H_{11}N_3O_6S$



bavisantum

bavisant (4-cyclopropylpiperazin-1-yl}){4-[(morpholin-4-yl)methyl]phenyl}methanone

bavisant (4-cyclopropylpipérazin-1-yl){4-[(morpholin-4-yl)méthyl]phényl}méthanone

bavisant (4-ciclopropilpiperazin-1-il){4-[(morfolin-4-il)metil]fenil}metanona

$C_{19}H_{27}N_3O_2$



bedaquilinum

bedaquiline

(1*R*,2*S*)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol

bédaquiline

(1*R*,2*S*)-1-(6-bromo-2-méthoxyquinoléin-3-yl)-4-(diméthylamino)-2-(naphtalén-1-yl)-1-phénylbutan-2-ol

bedaquilina

(1*R*,2*S*)-1-(6-bromo-2-metoxiquinolein-3-il)-4-(dimetilamino)-2-(naftalen-1-il)-1-fenilbutan-2-ol

$C_{32}H_{31}BrN_2O_2$



brentuximabum vedotinum #

brentuximab vedotin

immunoglobulin G1-kappa auristatin E conjugate, anti-[*Homo sapiens* TNFRSF8 (tumor necrosis factor receptor superfamily member 8, KI-1, CD30)], chimeric monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-446) [*Mus musculus* VH (IGHV1-84*02 -(IGHD)-IGHJ3*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01 CH3 K130>del (118-446)], (220-218')-disulfide (if not conjugated) with kappa light chain (1'-218') [*Mus musculus* V-KAPPA (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; (226-226'')-disulfide dimer; conjugated, on an average of 3 to 5 cysteinyl, to monomethylauristatin E (MMAE), via a maleimidecaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC) linker
For the *vedotin* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

brentuximab védotine

immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[*Homo sapiens* TNFRSF8 (membre 8 de la superfamille des récepteurs du facteur de nécrose tumorale, KI-1, CD30)], anticorps monoclonal chimérique conjugué à l'auristatine E;
chaîne lourde gamma1 (1-446) [*Mus musculus* VH (IGHV1-84*02 -(IGHD)-IGHJ3*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01 CH3 K130>del (118-446)], (220-218')-disulfure (si non conjugué) avec la chaîne légère kappa (1'-218') [*Mus musculus* V-KAPPA (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimère (226-226'')-disulfure; conjugué, sur 3 à 5 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker maléimidécaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC)
Pour la partie *védotine*, veuillez vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

brentuximab vedotina

inmunoglobulina G1-kappa conjugada con auristatina E, anti-[*Homo sapiens* TNFRSF8 (miembro 8 de la superfamilia de los receptores del factor de necrosis tumoral, KI-1, CD30)], anticuerpo monoclonal quimérico conjugado con auristatina E;
cadena pesada gamma1 (1-446) [*Mus musculus* VH (IGHV1-84*02 -(IGHD)-IGHJ3*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01 CH3 K130>del (118-446)], (220-218')-disulfuro (si non está conjugado) con la cadena ligera kappa (1'-218') [*Mus musculus* V-KAPPA (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimero (226-226'')-disulfuro; conjugado, en 3 a 5 residuos cisteinil en término medio, con monometilauristatina E (MMAE), mediante un conector maleimidecaproil-valil-citrulinil-*p*-aminobenzilcarbamato (mc-val-cit-PABC)
Por la parte *vedotina*, por favor, vaya al documento *"INN for pharmaceutical substances: Names for radicals, groups and others"**.

Heavy chain / Chaîne lourde / Cadena pesada

```
QIQLQQSGPE VVKPGASVKI SCKASGYTFT DYYITWVKQK PGQGLEWIGW  50
IYPGSGNTKY NEKFKGKATL TVDTSSSTAF MQLSSLTSED TAVYFCANYG 100
NYWFAYWGQG TQVTVSAAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQSPAS LAVSLGQRAT ISCKASQSVD FDGDSYMNWY QQKPGQPPKV  50
LIYAASNLES GIPARFSGSG SGTDFTLNIH PVEEEDAATY YCQQSNEDPW 100
TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    144-200    261-321    367-425
         22''-96''  144''-200''  261''-321''  367''-425''
Intra-L  23'-92'    138'-198'
         23'''-92'''  138'''-198'''
Inter-H-L *  220-218'   220''-218'''
Inter-H-H *  226-226''  229-229''
```

*Two or three of the inter-chain disulfide bridges are not present, the antibody being conjugated to an average of 3 to 5 drug linkers each via a thioether bond.
* Deux ou trois des ponts disulfure ne sont pas présents, l'anticorps étant conjugué à une moyenne de 3 à 5 linker-principe actif chacun via une liaison thioéther.
* Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado, con sendos enlaces tioéter, a una media de 3 a 5 conectores de principio activo

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
297, 297''

cenicrivirocum

cenicriviroc

8-{4-[2-(butoxy)ethoxy]phenyl}-1-(2-methylpropyl)-*N*-(4-{(*S*)-[(1-propyl-1*H*-imidazol-5-yl)methyl]sulfinyl}phenyl)-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide

cénicriviroc

8-{4-[2-(butoxy)éthoxy]phényl}-1-(2-méthylpropyl)-*N*-(4-{(*S*)-[(1-propyl-1*H*-imidazol-5-yl)méthyl]sulfinyl}phényl)-1,2,3,4-tétrahydro-1-benzazocine-5-carboxamide

cenicriviroc

8-{4-[2-(butoxi)etoxi]fenil}-1-(2-metilpropil)-*N*-(4-{(*S*)-[(1-propil-1*H*-imidazol-5-il)metil]sulfinil}fenil)-1,2,3,4-tetrahidro-1-benzazocina-5-carboxamida

$C_{41}H_{52}N_4O_4S$



cobicistatum

cobicistat — (1,3-thiazol-5-yl)methyl (5*S*,8*R*,11*R*)-8,11-dibenzyl-2-methyl-5-[2-(morpholin-4-yl)ethyl]-1-[2-(propan-2-yl)-1,3-thiazol-4-yl]-3,6-dioxo-2,4,7,12-tetraazatridecan-13-oate

cobicistat — (5*S*,8*R*,11*R*)-8,11-dibenzyl-2-méthyl-5-[2-(morpholin-4-yl)éthyl]-1-[2-(propan-2-yl)-1,3-thiazol-4-yl]-3,6-dioxo-2,4,7,12-tétraazatridécan-13-oate de (1,3-thiazol-5-yl)méthyle

cobicistat — (5*S*,8*R*,11*R*)-8,11-dibencil-2-metil-5-[2-(morfolin-4-il)etil]-1-[2-(propan-2-il)-1,3-tiazol-4-il]-3,6-dioxo-2,4,7,12-tetraazatridecan-13-oato de (1,3-tiazol-5-il)metilo

$C_{40}H_{53}N_7O_5S_2$



crizotinibum

crizotinib — 3-[(1*R*)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1*H*-pyrazol-4-yl]pyridin-2-amine

crizotinib — 3-[(1*R*)-1-(2,6-dichloro-3-fluorophényl)éthoxy]-5-[1-(pipéridin-4-yl)-1*H*-pyrazol-4-yl]pyridin-2-amine

crizotinib — 3-[(1*R*)-1-(2,6-dicloro-3-fluorofenil)etoxi]-5-[1-(piperidin-4-il)-1*H*-pirazol-4-il]piridin-2-amina

$C_{21}H_{22}Cl_2FN_5O$



dacomitinibum

dacomitinib — (2*E*)-*N*-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide

dacomitinib — (2*E*)-*N*-{4-[(3-chloro-4-fluorophényl)amino]-7-méthoxyquinazolin-6-yl}-4-(pipéridin-1-yl)but-2-énamide

dacomitinib — (2*E*)-*N*-{4-[(3-cloro-4-fluorofenil)amino]-7-metoxiquinazolin-6-il}-4-(piperidin-1-il)but-2-enamida

$C_{24}H_{25}ClFN_5O_2$



dexpramipexolum

dexpramipexole — (6*R*)-N^6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

dexpramipexole — (6*R*)-N^6-propyl-4,5,6,7-tétrahydro-1,3-benzothiazole-2,6-diamine

dexpramipexol — (6*R*)-N^6-propil-4,5,6,7-tetrahidro-1,3-benzotiazol-2,6-diamina

$C_{10}H_{17}N_3S$



drozitumabum #

drozitumab — immunoglobulin G1-lambda, anti-[*Homo sapiens* TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, DR5, death receptor 5, TRAIL-R2, TNF-related apoptosis-inducing ligand receptor 2, TR-2, CD262)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-20*01 (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfide with lambda light chain (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-19*01 (96.80%) -IGLJ3*01) [6.3.11] (1'-107') -IGLC3*03 (108'-213')]; (230-230'':233-233'')-bisdisulfide dimer

drozitumab — immunoglobuline G1-lambda, anti-[*Homo sapiens* TNFRSF10B (membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale, DR5, death receptor 5, TRAIL-R2, récepteur 2 du ligand inducteur d'une apoptose liée au TNF, TR-2, CD262)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-20*01 (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfure avec la chaîne légère lambda (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-19*01 (96.80%) -IGLJ3*01) [6.3.11] (1'-107') -IGLC3*03 (108'-213')]; dimère (230-230'':233-233'')-bisdisulfure

drozitumab

inmunoglobulina G1-lambda, anti-[*Homo sapiens* TNFRSF10B (miembro 10B de la superfamilia de receptores del factor de necrosis tumoral, DR5, receptor de muerte 5, TRAIL-R2, receptor 2 del ligando inductor de la apoptosis de la familiaTNF, TR-2, CD262)], anticuerpo monoclonal de *Homo sapiens* ;
cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-20*01 (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfuro con la cadena ligera lambda (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-19*01 (96.80%) -IGLJ3*01) [6.3.11] (1'-107') -IGLC3*03 (108'-213')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGGG VERPGGSLRL SCAASGFTFD DYAMSWVRQA PGKGLEWVSG  50
INWQGGSTGY ADSVKGRVTI SRDNAKNSLY LQMNSLRAED TAVYYCAKIL 100
GAGRGWYFDY WGKGTTVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
SELTQDPAVS VALGQTVRIT CSGDSLRSYY ASWYQQKPGQ APVLVIYGAN  50
NRPSGIPDRF SGSSSGNTAS LTITGAQAED EADYYCNSAD SSGNHVVFGG 100
GTKLTVLGQP KAAPSVTLFP PSSEELQANK ATLVCLISDF YPGAVTVAWK 150
ADSSPVKAGV ETTTPSKQSN NKYAASSYLS LTPEQWKSHK SYSCQVTHEG 200
STVEKTVAPT ECS                                          213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H   22-96     148-204     265-325     371-429
          22"-96"   148"-204"   265"-325"   371"-429"
Intra-L   21'-86'     135'-194'
          21'"-86'"   135'"-194'"
Inter-H-L   224-212'    224"-212'"
Inter-H-H   230-230"    233-233"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

301, 301"

dulaglutidum #

dulaglutide

glucagon-like peptide-1-immunoglobulin G4 fusion protein, [2-glycyl,16-L-glutamyl,30-glycyl][human glucagon-like peptide 1-(7-37)-peptide] {(8-A>G,22-G>E,36-R>G)-GLP-1(7-37)} fusion protein with tris(tetraglycyl-L-seryl)-L-alanine (linker) fusion protein with des-276-lysine-[57-L-proline,63-L-alanine,64-L-alanine]human immunoglobulin G4 Fc region {(10-S>P)-H-(4-F>A,5-L>A)-CH2-(107-K>-)-CH3 of IGHG4*01}, dimer (55-55':58-58')-bisdisulfide

dulaglutide

protéine de fusion entre le peptide 1 semblable au glucagon et l'immunoglobuline G4, [2-glycyl,16-L-glutamyl,30-glycyl][peptide 1 semblable au glucagon humain-(7-37)-peptide] {(8-A>G,22-G>E,36-R>G)GLP-1(7-37)} protéine de fusion avec le tris(tétraglycyl-L-séryl)-L-alanine (lien) protéine de fusion avec la dès-276-lysine-[57-L-proline,63-L-alanine,64-L-alanine]région Fc de l'immunoglobuline G4 humaine {(10-S>P)H-(4-F>A,5-L>A)CH2-(107-K>-)CH3 du IGHG4*01}, (55-55':58-58')-bisdisulfure du dimère

dulaglutida

proteína de fusión entre el péptido similar al glucagón 1 y la inmunoglobulina G4, [2-glicil,16-L-glutamil,30-glicil][péptido similar al glucagón humano 1-(7-37)-péptido] {(8-A>G,22-G>E,36-R>G)GLP-1(7-37)} proteína de fusión con el tris(tetraglicil-L-seril)-L-alanina (vínculo) proteína de fusión con la des-276-lisina-[57-L-prolina, 63-L-alanina,64-L-alanina]región Fc de la inmunoglobulina G4 humana {(10-S>P)H-(4-F>A,5-L>A)CH2-(107-K>-)CH3 del IGHG4*01}, (55-55':58-58')-bisdisulfuro del dímero

$C_{2646}H_{4044}N_{704}O_{836}S_{18}$

Monomer / Monomère / Monomero

```
HGEGTFTSDV  SSYLEEQAAK  EFIAWLVKGG  GGGGGSGGGG  SGGGGSAESK  50
YGPPCPPCPA  PEAAGGPSVF  LFPPKPKDTL  MISRTPEVTC  VVVDVSQEDP  100
EVQFNWYVDG  VEVHNAKTKP  REEQFNSTYR  VVSVLTVLHQ  DWLNGKEYKC  150
KVSNKGLPSS  IEKTISKAKG  QPREPQVYTL  PPSQEEMTKN  QVSLTCLVKG  200
FYPSDIAVEW  ESNGQPENNY  KTTPPVLDSD  GSFFLYSRLT  VDKSRWQEGN  250
VFSCSVMHEA  LHNHYTQKSL  SLSLG                            275
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
55-55' 58-58' 90-150 90'-150' 196-254 196'-254'

eliglustatum

eliglustat

N-{(1*R*,2*R*)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl}octanamide

éliglustat

N-{(1*R*,2*R*)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl}octanamide

eliglustat

N-{(1*R*,2*R*)-1-(2,3-dihidro-1,4-benzodioxin-6-il)-1-hidroxi-3-(pirrolidin-1-il)propan-2-il}octanamida

$C_{23}H_{36}N_2O_4$



elpamotidum

elpamotide

L-arginyl-L-phenylalanyl-L-valyl-L-prolyl-L-α-aspartylglycyl-L-asparaginyl-L-arginyl-L-isoleucine
human soluble (Vascular Endothelial Growth Factor Receptor) VEGFR2-(169-177)-peptide

elpamotide

L-arginyl-L-phénylalanyl-L-valyl-L-prolyl-L-α-aspartylglycyl-L-asparaginyl-L-arginyl-L-isoleucine
(Récepteur du Facteur de Croissance de l'Endothélium Vasculaire) RFCEV2 soluble humain-(169-177)-peptide

elpamotida

L-arginil-L-fenilalanil-L-valil-L-prolil-L-α-aspartilglicil-L-asparaginil-L-arginil-L-isoleucina
(receptor del factor de crecimiento endotelial vascular) RFCEV2 soluble humano-(169-177)-péptido

$C_{47}H_{76}N_{16}O_{13}$

H–Arg—Phe—Val—Pro—Asp—Gly—Asn—Arg—Ile–OH
9

ensituximabum #

ensituximab — immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC5AC (mucin 5AC, mucin 5 subtypes A and C tracheobronchial/gastric)], chimeric monoclonal antibody;
gamma1 heavy chain (1-443) [*Mus musculus* VH (IGHV2-3*01 - (IGHD)-IGHJ4*01) [8.7.7] (1-113) -*Homo sapiens* IGHG1*01 CH1 L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfide with kappa light chain (1'-213') [*Mus musculus* V-KAPPA (IGKV4-70*01 - IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; (222-222":225-225")-bisdisulfide dimer

ensituximab — immunoglobuline G1-kappa, anti-[*Homo sapiens* MUC5AC (mucine 5AC, mucine 5 de sous-types A et C trachéo-bronchique/gastrique)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-443) [*Mus musculus* VH (IGHV2-3*01 - (IGHD)-IGHJ4*01) [8.7.7] (1-113) -*Homo sapiens* IGHG1*01 CH1 L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfure avec la chaîne légère kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-70*01 -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (222-222":225-225")-bisdisulfure

ensituximab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* MUC5AC (mucina 5AC, mucina 5 de subtipos A y C traqueo-bronquial/gástrico], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-443) [*Mus musculus* VH (IGHV2-3*01 - (IGHD)-IGHJ4*01) [8.7.7] (1-113) -*Homo sapiens* IGHG1*01 CH1 L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfuro con la cadena ligera kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-70*01 - IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (222-222":225-225")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLKESGPD LVAPSQSLSI TCTVSGFSLS KFGVNWVRQP PGKGLEWLGV  50
IWGDGSTSYN SGLISRLSIS KENSKSQVFL KLNSLQADDT ATYYCVKPGG 100
DYWGHGTSVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC LVKDYFPEPV 150
TVSWNSGALT SGVHTFPAVL QSSGPYSLSS VVTVPSSSLG TQTYICNVNH 200
KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS 350
RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTM PPVLDSDGSF 400
FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK        443
```

Light chain / Chaîne légère / Cadena ligera

```
QVVLTQSPVI MSASPGEKVT MTCSASSSIS YMYWYQQKPG TSPKRWIYDT  50
SKLASGVPAR FSGSGSGTSY SLTISNMEAG DAATYYCHQR DSYPWTFGGG 100
TNLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-95 140-196 257-317 363-421
22"-95" 140"-196" 257"-317" 363"-421"
Intra-L 23'-87' 133'-193'
23'"-87'" 133'"-193'"
Inter-H-L 216-213' 216"-213'"
Inter-H-H 222-222" 225-225"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
293, 293"

eteplirsenum
eteplirsen

all-P-ambo-5'-{*P*-[4-({2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-*N,N*-dimethylphosphonamidate}-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-*P*,3'-dideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,3'-dideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoguanylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoguanylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoguanylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,3'-dideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoguanylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoguanylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,3'-dideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,3'-dideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,3'-dideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-*P*,3'-dideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-dimethylamino-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-2',3'-dideoxy-2',3'-imino-2',3'-secoguanosine

étéplirsen	*tout-P-ambo*-5'-{*P*-[4-({2-[2-(2-hydroxyéthoxy)éthoxy]éthoxy}carbonyl)pipérazin-1-yl]-*N,N*-diméthylphosphonamidate}-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-*P*,3'-didésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,3'-didésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,3'-didésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,3'-didésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-*P*,3'-didésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-*P*,3'-didésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-*P*,3'-didésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-*P*,2',3'-tridésoxy-*P*-diméthylamino-2',3'-imino-2',3'-sécoadenylyl-(2'a→5')-2',3'-didésoxy-2',3'-imino-2',3'-sécoguanosine

eteplirsén

todo-P-ambo-5'-{*P*-[4-({2-[2-(2-hidroxietoxi)etoxi]etoxi}carbonl)piperazin-1-il]-*N,N*-dimetilfosfonamidato}-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secocitidilil-(2'a→5')-*P*,3'-didesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secocitidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secocitidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secocitidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,3'-didesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secocitidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoadenil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoguanilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoguanilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoguanilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,3'-didesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secocitidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoadenill-(2'a→5')-*P*,3'-didesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,3'-didesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,3'-didesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secocitidilil-(2'a→5')-*P*,3'-didesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-dimetilamino-2',3'-imino-2',3'-secoadenilil-(2'a→5')-2',3'-didesoxi-2',3'-imino-2',3'-secoguanosina

$C_{364}H_{569}N_{177}O_{122}P_{30}$



B(1-30):
C-T-C-C-A-A-C-A-T-C-A-A-G-G-A-A-G-A-T-G-G-C-A-T-T-T-C-T-A-G

fasitibanti chloridum

fasitibant chloride

(4*S*)-4-amino-5-{4-[4-(2,4-dichloro-3-{[(2,4-dimethylquinolin-8-yl)oxy]methyl}benzenesulfonamido)oxane-4-carbonyl]piperazin-1-yl}-*N,N,N*-trimethyl-5-oxopentan-1-aminium chloride

chlorure de fasitibant

chlorure de (4*S*)-4-amino-5-{4-[4-(2,4-dichloro-3-{[(2,4-diméthylquinoléin-8-yl)oxy]méthyl}benzènesulfonamido)oxane-4-carbonyl]pipérazin-1-yl}-*N,N,N*-triméthyl-5-oxopentan-1-aminium

cloruro de fasitibant

cloruro de (4*S*)-4-amino-5-{4-[4-(2,4-dicloro-3-{[(2,4-dimetilquinolein-8-il)oxi]metil}bencenosulfonamido)oxano-4-carbonil]piperazin-1-il}-*N,N,N*-trimetil-5-oxopentan-1-aminio

$C_{36}H_{49}Cl_3N_6O_6S$



fedovapagonum

fedovapagon

(2*S*)-N^2,N^2-dimethyl-N^1-{[2-methyl-4-(2,3,4,5-tetrahydro-1*H*-1-benzazepine-1-carbonyl)phenyl]methyl}pyrrolidine-1,2-dicarboxamide

fédovapagon

(2*S*)-N^2,N^2-diméthyl-N^1-{[2-méthyl-4-(2,3,4,5-tétrahydro-1*H*-1-benzazépine-1-carbonyl)phényl]méthyl}pyrrolidine-1,2-dicarboxamide

fedovapagón

(2*S*)-N^2,N^2-dimetil-N^1-{[2-metil-4-(2,3,4,5-tetrahidro-1*H*-1-benzazepina-1-carbonil)fenil]metil}pirrolidina-1,2-dicarboxamida

$C_{27}H_{34}N_4O_3$



florbetapirum (^{18}F)

florbetapir (^{18}F)

4-[(1*E*)-2-(6-{2-[2-(2-[^{18}F]fluoroethoxy)ethoxy]ethoxy}pyridine-3-yl)ethen-1-yl]-*N*-methylaniline

florbétapir (^{18}F)

4-[(1*E*)-2-(6-{2-[2-(2-[^{18}F]fluoroéthoxy)éthoxy]éthoxy}pyridin-3-yl)éthén-1-yl]-*N*-méthylaniline

florbetapir (^{18}F)

4-[(1*E*)-2-(6-{2-[2-(2-[^{18}F]fluoroetoxi)etoxi]etoxi}piridin-3-il)eten-1-il]-*N*-metilanilina

$C_{20}H_{25}{}^{18}FN_2O_3$



fluciclatidum (^{18}F)

fluciclatide (^{18}F) — *N*^{6}-[(28*E*)-29-(4-[^{18}F]fluorophenyl)-5,25-dioxo-3,9,12,15,18,21,27-heptaoxa-6,24,28-triazanonacos-28-enoyl]-*N*^{2}-(sulfanylacetyl)-L-lysyl-L-cysteinyl-L-arginylglycyl-L-α-aspartyl-L-cysteinyl-L-phenylalanyl-*N*-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecyl)-L-cysteinamide cyclic (2→6)-disulfide cyclic (1→8)-thioether

fluciclatide (^{18}F) — (2→6)-disulfure cyclique et (1→8)-thioéther cyclique du *N*^{6}-[(28*E*)-29-(4-[^{18}F]fluorophényl)-5,25-dioxo-3,9,12,15,18,21,27-heptaoxa-6,24,28-triazanonacos-28-énoyl]-*N*^{2}-(2-sulfanylacétyl)-L-lysyl-L-cystéinyl-L-arginylglycyl-L-α-aspartyl-L-cystéinyl-L-phénylalanyl-1-*N*-(17-amino-13,17-dioxo-3,6,9,15-tétraoxa-12-azaheptadécyl)-L-cystéinamide

fluciclatida (^{18}F) — (2→6)-disulfuro cíclico y (1→8)-tioéter cíclico del *N*^{6}-[(28*E*)-29-(4-[^{18}F]fluorofenil)-5,25-dioxo-3,9,12,15,18,21,27-heptaoxa-6,24,28-triazanonacos-28-enoil]-*N*^{2}-(2-sulfanilacetil)-L-lisil-L-cisteinil-L-arginilglicil-L-α-aspartil-L-cisteinil-L-fenilalanil-1-*N*-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecil)-L-cisteinamida

$C_{75}H_{115}{}^{18}FN_{18}O_{27}S_3$



fluciclovinum (^{18}F)

fluciclovine (^{18}F) — (1*r*,3*r*)-1-amino-3[^{18}F]fluorocyclobutane-1-carboxylic acid

fluciclovine (^{18}F) — acide *trans*-1-amino-3-[^{18}F]fluorocyclobutane-1-carboxylique

fluciclovina (^{18}F) — ácido (1*r*,3*r*)-1-amino-3-[^{18}F]fluorociclobutano-1-carboxílico

$C_5H_8{}^{18}FNO_2$



flurpiridazum (^{18}F)

flurpiridaz (^{18}F) — 2-*tert*-butyl-4-chloro-5-({4-[(2-[^{18}F]fluoroethoxy)methyl]phenyl}methoxy)pyridazin-3(2*H*)-one

flurpiridaz (^{18}F) — 2-*tert*-butyl-4-chloro-5-({4-[(2-[^{18}F]fluoroéthoxy)méthyl]phényl}méthoxy)pyridazin-3(2*H*)-one

flurpiridaz (^{18}F) — 2-*terc*-butil-4-cloro-5-({4-[(2-[^{18}F]fluoroetoxi)metil]fenil}metoxi)piridazin-3(2*H*)-ona

$C_{18}H_{22}Cl^{18}FN_2O_3$



foralumabum #

foralumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-33*01 (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2 L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; (227-227'':230-230'')-bisdisulfide dimer

foralumab — immunoglobuline G1 -kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-448) [*Homo sapiens* (IGHV3-33*01 (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2 L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimère (227-227'':230-230'')-bisdisulfure

foralumab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon)], anticuerpo monoclonal de *Homo sapiens;* cadena pesada gamma1 (1-448) [*Homo sapiens* (IGHV3-33*01 (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2 L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dímero (227-227'':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGRSLRL SCAASGFKFS GYGMHWVRQA PGKGLEWVAV  50
IWYDGSKKYY VDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARQM 100
GYWHFDLWGR GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPEAEGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPLTFG 100
GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 145-201 262-322 368-426
22''-96'' 145''-201'' 262''-322'' 368''-426''
Intra-L 23'-88' 135'-195'
23'''-88''' 135'''-195'''
Inter-H-L 221-215' 221''-215'''
Inter-H-H 227-227'' 230-230''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
298, 298''

fosdevirinum
fosdevirine — methyl (*R*)-(2-carbamoyl-5-chloro-1*H*-indol-3-yl){3-[(1*E*)-2-cyanoethen-1-yl]-5-methylphenyl}phosphinate

fosdévirine — (*R*)-(2-carbamoyl-5-chloro-1*H*-indol-3-yl){3-[(1*E*)-2-cyanoéthén-1-yl]-5-méthylphényl}phosphinate de méthyle

fosdevirina — (*R*)-(2-carbamoil-5-cloro-1*H*-indol-3-il){3-[(1*E*)-2-cianoeten-1-il]-5-metilfenil}fosfinato de metilo

$C_{20}H_{17}ClN_3O_3P$



ganitumabum #
ganitumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV4-4*02 (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120-449)], (222-219')-disulfide with kappa light chain (1'-219') [*Homo sapiens* V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; (228-228'':231-231'')-bisdisulfide dimer

ganitumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IGF1R (récepteur du facteur de croissance 1 analogue à l'insuline, IGF1-R, IGF-1R, CD221)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV4-4*02 (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120-449)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [*Homo sapiens* V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure

ganitumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IGF1R (receptor del factor de crecimiento 1 análogo a la insulina, IGF1-R, IGF-1R, CD221)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV4-4*02 (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120-449)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [*Homo sapiens* V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSGTLSL TCAVSGGSIS SSNWWSWVRQ PPGKGLEWIG  50
EIYHSGSTNY NPSLKSRVTI SVDKSKNQFS LKLSSVTAAD TAVYYCARWT 100
GRTDAFDIWG QGTMVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTPGEPAS ISCRSSQSLL HSNGYNYLDW YLQKPGQSPQ  50
LLIYLGSNRA SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCMQGTHWP 100
LTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"
Intra-L	23'-93'	139'-199'		
	23'"-93'"	139'"-199'"		
Inter-H-L	222-219'	222"-219'"		
Inter-H-H	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

gataparsenum

gataparsen

all-P-ambo-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thioucytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyluridine

gataparsen

tout-*P*-*ambo*-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioguanylyl-(3'→5')-2'-déoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyluridine

gataparsén

todo-*P*-*ambo*-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioguanilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioguanilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metiluridina

$C_{204}H_{278}N_{59}O_{111}P_{17}S_{17}$

(3'→5')d(*P*-thio)(r<u>U</u>-r<u>G</u>-r<u>U</u>-r<u>G</u>-<u>C</u>-T-A-T-T-<u>C</u>-T-G-T-G-r<u>A</u>-r<u>A</u>-r<u>U</u>-r<u>U</u>)

Modified nucleosides / Nucléosides modifiés / Nucleosidos modificados:



gemigliptinum

gemigliptin

1-{(2*S*)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-*d*]pyrimidin-7(6*H*)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one

gémigliptine

1-{(2*S*)-2-amino-4-[2,4-bis(trifluorométhyl)-5,8-dihydropyrido[3,4-*d*]pyrimidin-7(6*H*)-yl]-4-oxobutyl}-5,5-difluoropipéridin-2-one

gemigliptina

1-{(2*S*)-2-amino-4-[2,4-bis(trifluorometil)-5,8-dihidropirido[3,4-*d*]pirimidin-7(6*H*)-il]-4-oxobutil}-5,5-difluoropiperidin-2-ona

$C_{18}H_{19}F_8N_5O_2$



iniparibum

iniparib	4-iodo-3-nitrobenzamide
iniparib	4-iodo-3-nitrobenzamide
iniparib	4-iodo-3-nitrobenzamida

$C_7H_5IN_2O_3$



insulinum tregopilum

insulin tregopil	$N^{6,29B}$-(4,7,10,13-tetraoxatetradecanoyl)human insulin
insuline trégopil	$N^{6,29B}$-(4,7,10,13-tétraoxatétradécanoyl)insuline humaine
insulina tregopilo	$N^{6,29B}$-(4,7,10,13-tetraoxatetradecanoil)insulina humana

$C_{267}H_{401}N_{65}O_{82}S_6$



ioflubenzamidum (^{131}I)

ioflubenzamide (^{131}I)	*N*-[2-(diethylamino)ethyl]-4-(4-fluorobenzamido)-5-[^{131}I]iodo-2-methoxybenzamide
ioflubenzamide (^{131}I)	*N*-[2-(diéthylamino)éthyl]-4-(4-fluorobenzamido)-5-[^{131}I]iodo-2-méthoxybenzamide
ioflubenzamida (^{131}I)	*N*-[2-(dietilamino)etil]-4-(4-fluorobenzamido)-5-[^{131}I]iodo-2-metoxibenzamida

$C_{21}H_{25}F^{131}IN_3O_3$



ioforminolum

ioforminol	*all-ambo*-5,5'-[2-hydroxypropane-1,3-diylbis(formylazanediyl)]bis[*N,N'*-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide]
ioforminol	*tout-ambo*-5,5'-[2-hydroxypropane-1,3-diylbis(formylazanediyl)]bis[*N,N'*-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzène-1,3-dicarboxamide]
ioforminol	*todo-ambo*-5,5'-[2-hidroxipropano-1,3-diilbis(formilazanodiil)]bis[*N,N'*-bis(2,3-dihidroxipropil)-2,4,6-triiodobenceno-1,3-dicarboxamida]

$C_{33}H_{40}I_6N_6O_{15}$



ipragliflozinum

ipragliflozin	(1*S*)-1,5-anhydro-1-*C*-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-D-glucitol
ipragliflozine	(1*S*)-1,5-anhydro-1-*C*-{3-[(1-benzothiophén-2-yl)méthyl]-4-fluorophényl}-D-glucitol
ipragliflozina	(1*S*)-1,5-anhidro-1-*C*-{3-[(1-benzotiofen-2-il)metil]-4-fluorofenil}-D-glucitol $C_{21}H_{21}FO_5S$



itarnafloxinum

itarnafloxin — 5-fluoro-*N*-{2-[(2*S*)-1-methylpyrrolidin-2-yl]ethyl}-3-oxo-6-[(3*RS*)-3-(pyrazin-2-yl)pyrrolidin-1-yl]-3*H*-benzo[*b*]pyrido[3,2,1-*kl*]phenoxazine-2-carboxamide

itarnafloxine — 5-fluoro-*N*-{2-[(2*S*)-1-méthylpyrrolidin-2-yl]éthyl}]-3-oxo-6-[3-(pyrazin-2-yl)pyrrolidin-1-yl]-3*H*-benzo[*b*]pyrido[3,2,1-*kl*]phénoxazine-2-carboxamide

itarnafloxina — 5-fluoro-*N*-{2-[(2*S*)-1-metilpirrolidin-2-il]etil}-3-oxo-6-[(3*RS*)-3-(pirazin-2-il)pirrolidin-1-il]-3*H*-benzo[*b*]pirido[3,2,1-*kl*]fenoxazina-2-carboxamida

$C_{35}H_{33}FN_6O_3$



itolizumabum #

itolizumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* CD6 (Tp120, T12)], humanized monoclonal antibody;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-17*01 (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer

itolizumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* CD6 (Tp120, T12)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-17*01 (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

itolizumab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD6 (Tp120, T12)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens* IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-17*01 (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVKPGGSLKL SCAASGFKFS RYAMSWVRQA PGKRLEWVAT  50
ISSGGSYIYY PDSVKGRFTI SRDNVKNTLY LQMSSLRSED TAMYYCARRD 100
YDLDYFDSWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASRDIR SYLTWYQQKP GKAPKTLIYY  50
ATSLADGVPS RFSGSGSGQD YSLTISSLES DDTATYYCLQ HGESPFTLGS 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"
Intra-L	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L	222-214'	222"-214'"		
Inter-H-H	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

lorvotuzumabum mertansinum #

lorvotuzumab mertansine	immunoglobulin G1-kappa, anti-[*Homo sapiens* NCAM1 (neural cell adhesion molecule 1, CD56, NCAM-1)], humanized monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV3-30*03 (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*02 (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (227-227":230-230")-bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a thiopentanoate linker For the *mertansine* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"**
lorvotuzumab mertansine	immunoglobuline G1-kappa, anti-[*Homo sapiens* NCAM1 (molécule d'adhésion 1 de cellule neurale, CD56, NCAM-1)], anticorps monoclonal humanisé conjugué au maytansinoïde DM1; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV3-30*03 (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*02 (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (227-227":230-230")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker thiopentanoate Pour la partie *mertansine*, veuillez vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

lorvotuzumab mertansina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* NCAM1 (molécula de adhesión 1 de celula neural, CD56, NCAM-1)], anticuerpo monoclonal humanizado conjugado con maitansinoide DM1; cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV3-30*03 (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-30*02 (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimero (227-227":230-230")-bisdisulfuro; conjugado, en 3 a 4 residuos lisil por término medio, con maitansinoide DM1 con un conector tiopentanoato
Por la parte *mertansina*, por favor, vaya al documento *"INN for pharmaceutical substances: Names for radicals, groups & others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SFGMHWVRQA PGKGLEWVAY  50
ISSGSFTIYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARMR 100
KGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTLGQPAS ISCRSSQIII HSDGNTYLEW FQQRPGQSPR  50
RLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP 100
HTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    145-201    262-322    368-426
         22"-96"  145"-201"  262"-322"  368"-426"
Intra-L  23'-93'   139'-199'
         23'"-93'" 139'"-199'"
Inter-H-L  221-219'  221"-219'"
Inter-H-H  227-227"  230-230"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
298, 298"

maraciclatidum

maraciclatide

N^6-(5-{[5-{[3-(hydroxyimino)-2-methylbutan-2-yl]amino}-3-(2-{[3-(hydroxyimino)-2-methylbutan-2-yl]amino}ethyl)pentyl]amino}-5-oxopentanoyl)-N^2-(2-sulfanylacetyl)-L-lysyl-L-cysteinyl-L-arginylglycyl-L-α-aspartyl-L-cysteinyl-L-phenylalanyl-*N*-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecyl)-L-cysteinamide cyclic (2→6)-disulfide cyclic (1→8)-thioether

maraciclatide

(2→6)-disulfure cyclique et (1→8)-thioéther cyclique du N^6-(5-{[5-{[3-(hydroxyimino)-2-méthylbutan-2-yl]amino}-3-(2-{[3-(hydroxyimino)-2-méthylbutan-2-yl]amino}éthyl)pentyl]amino}-5-oxopentanoyl)-N^2-(2-sulfanylacétyl)-L-lysyl-L-cystéinyl-L-arginylglycyl-L-α-aspartyl-L-cystéinyl-L-phénylalanyl-1-*N*-(17-amino-13,17-dioxo-3,6,9,15-tétraoxa-12-azaheptadécyl)-L-cystéinamide

maraciclatida

(2→6)-disulfuro cíclico y (1→8)-tioéter cíclico del N^6-(5-{[5-{[3-(hidroxiimino)-2-metilbutan-2-il]amino}-3-(2-{[2-(hidroxiimino)-2-metilbutan-2-il]amino}etil)pentil]amino}-5-oxopentanoil)-N^2-(2-sulfanilacetil)-L-lisil-L-cisteinil-L-ar3inilglicil-L-α-aspartil-L-cisteinil-L-fenilalanil-1-*N*-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecil)-L-cisteinamida

$C_{72}H_{120}N_{20}O_{21}S_3$



metformini glycinas

metformin glycinate	*N*,*N*-dimethyl-1,2,3-triimidodicarbonic diamide glycinate (1:1)
glycinate de metformine	glycinate du diamide *N*,*N*-diméthyl-1,2,3-triimidodicarbonique (1:1)
glicinato de metformina	glicinato de la diamida *N*,*N*-dimetil-1,2,3-triimidodicarbóníco (1:1)

$C_4H_{11}N_5 \cdot C_2H_5NO_2$



mibampatorum

mibampator	*N*-[(2*R*)-2-{4'-[2-(methanesulfonamido)ethyl][1,1'-biphenyl]-4-yl}propyl]propane-2-sulfonamide
mibampator	*N*-[(2*R*)-2-{4'-[2-(méthanesulfonamido)éthyl][1,1'-biphényl]-4-yl}propyl]propane-2-sulfonamide
mibampator	*N*-[(2*R*)-2-{4'-[2-(metanosulfonamido)etil][1,1'-bifenil]-4-il}propil]propano-2-sulfonamida

$C_{21}H_{30}N_2O_4S_2$



navitoclaxum

navitoclax — 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-*N*-(4-{[(2*R*)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-(trifluoromethanesulfonyl)benzenesulfonyl]benzamide

navitoclax — 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-*N*-(4-{[(2*R*)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-(trifluoromethanesulfonyl)benzenesulfonyl]benzamide

navitoclax — 4-(4-{[2-(4- clorofenil)-5,5- dimetilciclohex -1-en-1-il]metil}piperazin-1-il)-*N*-(4-{[(2*R*)-1-(fenilsulfanil)-4-(morfolin-4-il)-butan-2-il]amino}-3-(trifluorometanosulfonil)bencenosulfonil]benzamida

$C_{47}H_{55}ClF_3N_5O_6S_3$



nonacogum beta pegolum #

nonacog beta pegol — pegylated human blood coagulation factor IX; human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), en average of one sialyl unit of the N-linked carbohydrates are 5-*N*-[*N*-({2,3-bis[ω-methoxypoly(oxyethane-1,2-diyl)]propoxy}carbonyl)glycyl]-5-*N*-deacetyl

nonacog bêta pégol — facteur IX humain de coagulation sanguine, pégylé; facteur IX humain de coagulation (EC 3.4.21.22, facteur Christmas, facteur antihémophile B) dont quelques unités sialyl, en moyenne une par molécule d'enzyme, de la partie N-glycosyl sont 5-*N*-[*N*-({2,3-bis[ω-méthoxypoly(oxyéthylène)]propoxy}carbonyl)glycyl]-5-*N*-désacétyl

nonacog beta pegol — factor IX humano de coagulación sanguínea, pegilado; factor IX humano de coagulación (EC 3.4.21.22, factor Christmas, factor antihemofilico B) algunas de cuyas unidades sialil, una por molécula de enzima, por término medio, de la fracción N-glicosil son 5-*N*-[*N*-({2,3-bis[ω-metoxipoli(oxietilen)]propoxi}carbonil)glicil]-5-*N*-desacetil

```
YNSGKLEEFV QGNLERECME EKCSFEEARE VFENTERTTE FWKQYVDGDQ 50
CESNPCLNGG SCKDDINSYE CWCPFGFEGK NCELDVTCNI KNGRCEQFCK 100
NSADNKVVCS CTEGYRLAEN QKSCEPAVPF PCGRVSVSQT SKLTRAEAVF 150
PDVDYVNSTE AETILDNITQ STQSFNDFTR VVGGEDAKPG QFPWQVVLNG 200
KVDAFCGGSI VNEKWIVTAA HCVETGVKIT VVAGEHNIEE TEHTEQKRNV 250
IRIIPHHNYN AAINKYNHDI ALLELDEPLV LNSYVTPICI ADKEYTNIFL 300
KFGSGYVSGW GRVFHKGRSA LVLQYLRVPL VDRATCLRST KFTIYNNMFC 350
AGFHEGGRDS CQGDSGGPHV TEVEGTSFLT GIISWGEECA MKGKYGIYTK 400
VSRYVNWIKE KTKLT                                    415
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
18-23 51-62 56-71 73-82 88-99 95-109
111-124 132-289 206-222 336-350 361-389

Modified residues / Résidus modifiés / Residuos modificados

E
7-8-15-17-20-21-26-27-30-33-36-40
4-carboxyGlu



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-157 Asn-167



R = α-Sia, R' = α-Sia or PEG-α-Sia or R' = α-Sia, R = α-Sia or PEG-α-Sia

Gal = D-galactopyranosyl
Gl-*N* = 2-(acetylamino)-2-deoxy-D-glucopyranosyl
Man = D-mannopyranosyl
PEG- = *O*-[α-methylpoly(oxyethylene) hydrogen phosphate]
Sia = 5-*N*-acetyl-α-neuramin-2-yl

Other positions of post-translational modifications:
partial-hydroxylation of Asp64; O-linked glycosylation on positions Ser53 and Ser61, partially O-linked glycosylation on positions Thr159 and Thr169

Autres positions de modifications post-traductionelles:
hydroxylation partielle de Asp64; glycosylation O-liée sur les positions Sér53 et Sér61, glycosylation partielle O-liée sur les positions Thr159 et Thr169

Otras posiciones de modificaciones post-traducción
hidroxilación parcial de Asp64; glicosilación O-ligada en las posiciones Ser53 y Ser61, glicosilación parcial O-ligada en las posiciones Thr159 y Thr169

obinutuzumabum #

obinutuzumab

immunoglobulin G1, anti-[*Homo sapiens* CD20 (membrane-spanning 4-domains subfamily A member 1, MS4A1, B lymphocyte surface antigen B1, Leu-16, Bp35)], humanized monoclonal antibody, GA101;
gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*01 (120-448)], (222-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer
immunomodulator

obinutuzumab

immunoglobuline G1, anti-[*Homo sapiens* CD20 (membre 1 de la sous-famille A à 4 domaines transmembranaires, MS4A1, antigène de surface B1 des lymphocytes B, Leu-16, Bp35)], anticorps monoclonal humanisé, GA101;
chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*01 (120-448)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ4*01) [11.3.9] (1'-112') - *Homo sapiens* IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure
immunomodulateur

obinutuzumab

inmunoglobulina G1, anti-[*Homo sapiens* CD20 (miembro 1 de la sub-familia A de 4 dominios transmembranarios, MS4A1, antígeno de superficie B1 de los linfocitos B, Leu-16, Bp35)], anticuerpo monoclonal humanizado, GA101;
cadena pesada gamma1 (1-448) [VH humanizada (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*01 (120-448)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ4*01) [11.3.9] (1'-112') - *Homo sapiens* IGKC*01 (113'-219')]; dímero (228-228'':231-231'')-bisdisulfuro
inmunomodulador

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYAFS YSWINWVRQA PGQGLEWMGR  50
IFPGDGDTDY NGKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARNV 100
FDGYWLVYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQTPLS LPVTPGEPAS ISCRSSKSLL HSNGITYLYW YLQKPGQSPQ  50'
LLIYQMSNLV SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCAQNLELP 100'
YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150'
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200'
VTHQGLSSPV TKSFNRGEC                                    219'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
22-96    22''-96''    23'-93'    23'''-93'''  139'-199'  139'''-199'''  146-202  146''-202''
219'-222 219'''-222'' 228-228''  231-231''    263-323    263''-323''    369-427  369''-427''
```

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

```
Ser-53  Ser-61  Asn-157  Thr-159  Asn-167  Thr-169
```

olaratumabum #

olaratumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* PDGFRA (platelet-derived growth factor receptor alpha subunit, CD140a, PDGFR2)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-457) [*Homo sapiens* VH (IGHV4-39*01 (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03 (128-457)], (230-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (236-236'':239-239'')-bisdisulfide dimer

olaratumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* PDGFRA (sous-unité alpha du récepteur du facteur de croissance dérivé des plaquettes, CD140a, PDGFR2)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-457) [*Homo sapiens* VH (IGHV4-39*01 (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03 (128-457)], (230-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (236-236'':239-239'')-bisdisulfure

olaratumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* PDGFRA (subunidad alfa del receptor del factor de crecimiento derivado de las plaquetas, CD140a, PDGFR2)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-457) [*Homo sapiens* VH (IGHV4-39*01 (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03 (128-457)], (230-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimero (236-236":239-239")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QLQLQESGPG LVKPSETLSL TCTVSGGSIN SSSYYWGWLR QSPGKGLEWI  50
GSFFYTGSTY YNPSLRSRLT ISVDTSKNQF SLMLSSVTAA DTAVYYCARQ 100
STYYYGSGNY YGWFDRWDQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV 250
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 400
YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS 450
LSLSPGK                                               457
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPAFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                       214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-97     154-210    271-331    377-435
         22"-97"   154"-210"  271"-331"  377"-435"
Intra-L  23'-88'   134'-194'
         23"'-88"' 134"'-194"'
Inter-H-L  230-214'  230"-214"'
Inter-H-H  236-236"  239-239"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
30, 30", 307, 307"

olokizumabum #

olokizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* IL6 (interleukin 6; IL-6)], humanized monoclonal antibody;
gamma4 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -*Homo sapiens* IGHG4*01 hinge S10(228)>P (121-447)], (134-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (226-226":229-229")-bisdisulfide dimer

olokizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens Homo sapiens* IL6 (interleukine 6; IL-6)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-447) [VH humanisé (*Homo sapiens* IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -*Homo sapiens* IGHG4*01 charnière S10(228)>P (121-447)], (134-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (226-226":229-229")-bisdisulfure

olokizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens Homo sapiens* IL6 (interleukina 6; IL-6)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-447) [VH humanizado (*Homo sapiens* IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -*Homo sapiens* IGHG4*01 bisagra S10(228)>P (121-447)], (134-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFNFN DYFMNWVRQA PGKGLEWVAQ  50
MRNKNYQYGT YYAESLEGRF TISRDDSKNS LYLQMNSLKT EDTAVYYCAR 100
ESYYGFTSYW GQGTLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200
YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCQASQDIG ISLSWYQQKP GKAPKLLIYN  50
ANNLADGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCLQ HNSAPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-98 147-203 261-321 367-425
22"-98" 147"-203" 261"-321" 367"-425"
Intra-L 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L 134-214' 134"-214'"
Inter-H-H 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
297, 297"

opicaponum

opicapone

2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl]-4,6-dimethylpyridine *N*-oxide

opicapone

N-oxyde de 2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophényl)-1,2,4-oxadiazol-3-yl]-4,6-diméthylpyridine

opicapona

N-óxido de 2,5-dicloro-3-[5-(3,4-dihidroxi-5-nitrofenil)-1,2,4-oxadiazol-3-il]-4,6-dimetilpiridina

$C_{15}H_{10}Cl_2N_4O_6$



orantinibum

orantinib

3-(2,4-dimethyl-5-{[(3*Z*)-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene]methyl}-1*H*-pyrrol-3-yl)propanoic acid

orantinib

acide 3-(2,4-diméthyl-5-{[(3*Z*)-2-oxo-1,2-dihydro-3*H*-indol-3-ylidène]méhyl}-1*H*-pyrrol-3-yl)propanoïque

orantinib

ácido 3-(2,4-dimetil-5-{[(3*Z*)-2-oxo-1,2-dihidro-3*H*-indol-3-ilideno]metil}-1*H*-pirrol-3-il)propanoico



oxelumabum #

oxelumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFSF4 (Tumor necrosis factor ligand superfamily member 4, OX40 ligand, OX-40L, TAX transcriptionally-activated glycoprotein 1, TXGP1, gp34, CD252], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01 K130>del (121-449)], (223-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (229-229":232-232")-bisdisulfide dimer

oxélumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFSF4 (membre 4 de la superfamille des ligands du facteur de nécrose tumorale, ligand de OX40, OX40L, glycoprotéine 1 activée transcriptionellement par TAX, TXGP1, CD252], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01 K130>del (121-449)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (229-229":232-232")-bisdisulfure

oxelumab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFSF4 (miembro 4 de la superfamilia de ligandos del factor de necrosis tumoral, ligando de OX40, OX40L, glicoproteína 1 activada por transcripción por TAX, TXGP1, CD252], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01 K130>del (121-449)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
```
EVQLLESGGG LVQPGGSLRL SCAASGFTFN SYAMSWVRQA PGKGLEWVSI  50
ISGSGGFTYY ADSVKGRFTI SRDNSRTTLY LQMNSLRAED TAVYYCAKDR 100
LVAPGTFDYW GQGALVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
```

Light chain / Chaîne légère / Cadena ligera
```
DIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNSYPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"
Intra-L 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L 223-214' 223"-214'"
Inter-H-H 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
300, 300"

pegdinetanibum #

pegdinetanib

94 residues protein derived from human fibronectin 10th type III domain, pegylated:
glycyl[1438-L-arginine(D>R),1439-L-histidine(A>H),1441-L-histidine(A>H),1442-L-phenylalanine(V>F),1443-L-proline(T>P),1444-L-threonine(V>T),1467-L-leucine(G>L),1468-L-glutamine(S>Q),1469-L-proline(K>P),1470-L-proline(S>P),1492-L-aspartic acid(G>D),1493-glycine(R>G),1494-L-arginine(G>R),1495-L-asparagine(D>N),1496-glycine(S>G),1497-L-arginine(P>R),1498-L-leucine(A>L),1499-L-leucine(S>L),1501-L-isoleucine(K>I),1515-*S*-[(3*RS*)-1-(1-{[α-methylpoly(oxyethylene)]carbamoyl}-3-[({[α-methylpoly(oxyethylene)]carbamoyl}oxy)methyl]-8,13-dioxo-1,4-dioxa-9,12-diazapentadecan-15-yl)-2,5-dioxopyrrolidin-3-yl]-L-cysteine(S>C)]human fibronectin-(1424-1516)-peptide

pegdinétanib

protéine de 94 résidus derivée du 10ème domaine de type III de la fibronectine humaine pégylée :
glycyl[1438-L-arginine(D>R),1439-L-histidine(A>H),1441-L-histidine(A>H),1442-L-phénylalanine(V>F),1443-L-proline(T>P),1444-L-thréonine(V>T),1467-L-leucine(G>L),1468-L-glutamine(S>Q),1469-L-proline(K>P),1470-L-proline(S>P),1492-acide L-aspartique(G>D),1493-glycine(R>G),1494-L-arginine(G>R),1495-L-asparagine(D>N),1496-glycine(S>G),1497-L-arginine(P>R),1498-L-leucine(A>L),1499-L-leucine(S>L),1501-L-isoleucine(K>I),1515-*S*-[(3*RS*)-1-(1-{[α-méthylpoly(oxyéthylène)]carbamoyl}-3-[({[α-méthylpoly(oxyéthylène)]carbamoyl}oxy)méthyl]-8,13-dioxo-1,4-dioxa-9,12-diazapentadécan-15-yl)-2,5-dioxopyrrolidin-3-yl]-L-cystéine(S>C)]fibronectine humaine-(1424-1516)-peptide

pegdinetanib

proteína de 94 residuos derivada del décimo dominio de tipo III de la fibronectina humana pegilada :
glicil[1438-L-arginina(D>R),1439-L-histidina(A>H),1441-L-histidina(A>H),1442-L-fenilalanina(V>F),1443-L-prolina(T>P),1444-L-treonina(V>T),1467-L-leucina(G>L),1468-L-glutamina(S>Q),1469-L-prolina(K>P),1470-L-prolina(S>P),1492-ácido L-aspártico(G>D),1493-glicina(R>G),1494-L-arginina(G>R),1495-L-asparagina(D>N),1496-glicina(S>G),1497-L-arginina(P>R),1498-L-leucina(A>L),1499-L-leucina(S>L),1501-L-isoleucina(K>I),1515-*S*-[(3*RS*)-1-(1-{[α-metilpoli(oxietileno)]carbamoil}-3-[({[α-metilpoli(oxietileno)]carbamoil}oxi)metil]-8,13-dioxo-1,4-dioxa-9,12-diazapentadecan-15-il)-2,5-dioxopirrolidin-3-il]-L-cisteína(S>C)]fibronectina humana-(1424-1516)-péptido

```
                                    GEVVAATP TSLLISWRHP HFPTRYYRIT 1450
YGETGGNSPV QEFTVPLQPP TATISGLKPG VDYTITVYAV TDGRNGRLLS 1500
IPISINYRTE IDKPCQ                                       1516
```

Modified residue / Résidu modifié / Residuo modificado



peginesatidum #

peginesatide

pegylated erythropoietin receptor agonist, $N^{6.21}$,$N^{6.21'}$-{[(N^2,N^6-bis{[ω-methoxypoly(oxyethylene)]carbonyl}-L-lysyl-β-alanyl)imino]bis(methylenecarbonyl)}bis[*N*-acetylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(naphthalen-1-yl)-L-alanyl-L-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-*N*-methylglycyl-L-lysinamide] (6→15:6'→15')-bisdisulfure cyclic

péginésatide

agoniste du récepteur de l'érythropoïétine, pégylé (6→15:6'→15')-bisdisulfure cyclique du $N^{6.21}$,$N^{6.21'}$-{[(N^2,N^6-bis{[ω-méthoxypoly(oxyéthylène)]carbonyl}-L-lysyl-β-alanyl)imino]bis(méthylènecarbonyl)}bis[acétylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cystéinyl-L-histidyl-L-méthionylglycyl-L-prolyl-L-isoleucyl-L-thréonyl-3-(naphtalén-1-yl)-L-alanyl-L-valyl-L-cystéinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-*N*-méthylglycyl-L-lysinamide]

peginesatida

agonista del receptor de la eritropoyetina, pegilado (6→15:6'→15')-bisdisulfuro cíclico del $N^{6.21}$,$N^{6.21'}$-{[(N^2,N^6-bis{[ω-metoxipoli(oxietileno)]carbonil}-L-lisil-β-alanil)imino]bis(metilenocarbonil)}bis{S^6,S^{15}-ciclo[*N*-acetilglicilglicil-L-leucil-L-tirosil-L-alanil-L-cisteinil-L-histidil-L-metionilglicil-L-prolil-L-isoleucil-L-treonil-3-(naftalen-1-il)-L-alanil-L-valil-L-cisteinil-L-glutaminil-L-prolil-L-leucil-L-arginil-*N*-metilglicil-L-lisinamida]

$C_{231}H_{350}N_{62}O_{58}S_6[C_2H_4O]_n$







ponesimodum

ponesimod — (2*Z*,5*Z*)-5-{3-chloro-4-[(2*R*)-2,3-dihydroxypropoxy]phenylmethylidene}-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-4-one

ponésimod — (2*Z*,5*Z*)-5-{3-chloro-4-[(2*R*)-2,3-dihydroxypropoxy]phénylméthylidène}-3-(2-méthylphényl)-2-(propylimino)-1,3-thiazolidin-4-one

ponesimod — (2*Z*,5*Z*)-5-{3-cloro-4-[(2*R*)-2,3-dihidroxipropoxi]fenilmetilideno}-3-(2-metilfenil)-2-(propilimino)-1,3-tiazolidin-4-ona

$C_{23}H_{25}ClN_2O_4S$



rezatomidinum

rezatomidine — 4-[(1*S*)-1-(2,3-dimethylphenyl)ethyl]-1,3-dihydro-2*H*-imidazol-2-thione

rézatomidine — 4-[(1*S*)-1-(2,3-diméthylphényl)éthyl]-1,3-dihydro-2*H*-imidazole-2-thione

rezatomidina — 4-[(1*S*)-1-(2,3-dimetilfenil)etil]-1,3-dihidro-2*H*-imidazol-2-tiona

$C_{13}H_{16}N_2S$



roledumabum #

roledumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* RHD (Rhesus blood group D antigen, RhD, CD240D)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-456) [*Homo sapiens* VH (IGHV3-30*01 (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)], (229-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R, K127>T) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (235-235'':238-238'')-bisdisulfide dimer

rolédumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* RHD (antigène groupe sanguin Rhésus D, RhD, CD240D)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-456) [*Homo sapiens* VH (IGHV3-30*01 (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)], (229-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R, K127>T) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (235-235":238-238")-bisdisulfure
roledumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* RHD (antígeno sanguíneo D Rhesus, RhD, CD240D)], anticuerpo monoclonal de *Homo sapiens* ; cadena pesada gamma1 (1-456) [*Homo sapiens* VH (IGHV3-30*01 (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)], (229-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R, K127>T) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (235-235":238-238")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGRSLRL SCTASGFTFK NYAMHWVRQA PAKGLEWVAT  50
ISYDGRNIQY ADSVKGRFTF SRDNSQDTLY LQLNSLRPED TAVYYCARPV 100
RSRWLQLGLE DAFHIWGQGT MVTVSSASTK GPSVFPLAPS SKSTSGGTAA 150
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF 250
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300
REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG 350
QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 400
KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL 450
SLSPGK                                                 456
```

Light chain / Chaîne légère / Cadena ligera

```
AIRMTQSPSS FSASTGDRVT ITCRASQDIR NYVAWYQQKS GKAPKFLIYA  50
ASTLQSGVPS RFSGSGSGTD FTLTINSLQS EDFATYYCQQ YYNSPPTFGQ 100
GTRVEITRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    153-209   270-330   376-434
         22"-96"  153"-209" 270"-330" 376"-434"
Intra-L  23'-88'   134'-194'
         23'"-88'" 134'"-194'"
Inter-H-L  229-214'  229"-214'"
Inter-H-H  235-235"  238-238"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
306, 306"

ruxolitinibum

ruxolitinib	(3*R*)-3-cyclopentyl-3-[4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1*H*-pyrazol-1-yl]propanenitrile
ruxolitinib	(3*R*)-3-cyclopentyl-3-[4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1*H*-pyrazol-1-yl]propanenitrile
ruxolitinib	(3*R*)-3-ciclopentil-3-[4-(7*H*-pirrolo[2,3-*d*]pirimidin-4-il)-1*H*-pirazol-1-il]propanonitrilo

$C_{17}H_{18}N_6$



samalizumabum #

samalizumab	immunoglobulin G2-kappa, anti-[*Homo sapiens* CD200 (OX-2)], humanized monoclonal antibody; gamma2 heavy chain (1-442) [humanized VH (*Homo sapiens* IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 CH1-hinge-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (219-219":220-220":223-223":226-226")-tetrakisdisulfide dimer
samalizumab	immunoglobuline G2-kappa, anti-[*Homo sapiens* CD200 (OX-2)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-442) [VH humanisé (*Homo sapiens* IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 CH1-charnière-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (219-219":220-220":223-223":226-226")-tétrakisdisulfure
samalizumab	inmunoglobulina G2-kappa, anti-[*Homo sapiens* CD200 (OX-2)], anticuerpo monoclonal humanizado; cadena pesado gamma2 (1-442) [humanizado VH (*Homo sapiens* IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 CH1-bisagra-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada(*Homo sapiens* IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (219-219":220-220":223-223":226-226")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGSE LKKPGASVKI SCKASGYSFT DYIILWVRQN PGKGLEWIGH  50
IDPYYGSSNY NLKFKGRVTI TADQSTTTAY MELSSLRSED TAVYYCGRSK 100
RDYFDYWGQG TTLTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SNFGTQTYTC 200
NVDHKPSNTK VDKTVERKCC VECPPCPAPP VAGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LG         442
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASIGDRVT ITCKASQDIN SYLSWFQQKP GKAPKLLIYR  50
ANRLVDGVPS RFSGSGSGTD YTLTISSLQP EDFAVYYCLQ YDEFPYTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 144-200 257-317 363-421
22"-96" 144"-200" 257"-317" 363"-421"
Intra-L 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L 131-214' 131"-214'"
Inter-H-H 219-219" 220-220" 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
293, 293"

simenepagum

simenepag — 5-({[(2*R*)-1-{4-[(1*S*)-1-hydroxyhexyl]phenyl}-5-oxopyrrolidin-2-yl]methoxy}methyl)thiophene-2-carboxylic acid

siménépag — acide 5-({[(2*R*)-1-{4-[(1*S*)-1-hydroxyhexyl]phényl}-5-oxopyrrolidin-2-yl]méthoxy}méthyl)thiophène-2-carboxylique

simenepag — ácido 5-({[(2*R*)-1-{4-[(1*S*)-1-hidroxihexil]fenil}-5-oxopirrolidin-2-il]metoxi}metil)tiofeno-2- carboxílico

$C_{23}H_{29}NO_5S$



somatropinum pegolum #

somatropin pegol — $N^{5.141}$-[(2*E*)-({2-[({2,3-bis[ω-methoxypoly(oxyethylene)]propoxy}= carbonyl)amino]ethoxy}imino)ethyl]human somatotropin (growth hormone)

somatropine pégol — $N^{5.141}$-[(2*E*)-({2-[({2,3-bis[ω-méthoxypoly(oxyéthylène)]propoxy}= carbonyl)amino]éthoxy}imino)éthyl]somatotropine humaine (hormone de croissance)

somatropina pegol — $N^{5.141}$-[(2*E*)-({2-[({2,3-bis[ω-metoxipoli(oxietileno)]propoxi}carbonil)= amino]etoxi}imino)etil]somatotropina humana (hormona de crecimiento)

```
FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT  50
SLCFSESIPT PSNREETQQK SNLELLRISL LLIQSWLEPV QFLRSVFANS 100
LVYGASDSNV YDLLKDLEEG IQTLMGRLED GSPRTGQIFK QTYSKFDTNS 150
HNDDALLKNY GLLYCFRKDM DKVETFLRIV QCRSVEGSCG F         191
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
53-165 182-189

Modified residue / Résidu modifié / Residuo modificado

Q
Gln(141)



taprenepagum

taprenepag — 2-{3-[(*N*-{[4-(1*H*-pyrazol-1-yl)phenyl]methyl}pyridine-3-sulfonamido)methyl]phenoxy}acetic acid

taprénépag — acide 2-{3-[(*N*-{[4-(1*H*-pyrazol-1-yl)phényl]méthyl}pyridine-3-sulfonamido)méthyl]phénoxy}acétique

taprenepag — ácido 2-{3-[(*N*-{[4-(1*H*-pirazol-1-il)fenil]metil}piridina-3-sulfonamido)metil]fenoxi}acético

$C_{24}H_{22}N_4O_5S$



tedalinabum

tedalinab — (4*S*,7*R*)-*N*-*tert*-butyl-1-(2,4-difluorophenyl)-4,5,6,7-tetrahydro-1*H*-4,7-methanoindazole-3-carboxamide

tédalinab — (4*S*,7*R*)-*N*-*tert*-butyl-1-(2,4-difluorophényl)-4,5,6,7-tétrahydro-1*H*-4,7-méthanoindazole-3-carboxamide

tedalinab — (4*S*,7*R*)-*N*-*terc*-butil-1-(2,4-difluorofenil)-4,5,6,7-tetrahidro-1*H*-4,7-metanoindazol-3-carboxamida

$C_{19}H_{21}F_2N_3O$



tegobuvirum

tegobuvir — 5-({6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl}methyl)-2-(2-fluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine

tégobuvir — 5-({6-[2,4-bis(trifluorométhyl)phényl]pyridazin-3-yl}méthyl)-2-(2-fluorophényl)-5*H*-imidazo[4,5-*c*]pyridine

tegobuvir — 5-({6-[2,4-bis(trifluorometil)fenil]piridazin-3-il}metil)-2-(2-fluorofenil)-5*H*-imidazo[4,5-*c*]piridina

$C_{25}H_{14}F_7N_5$



telapristonum

telapristone — 11β-[4-(dimethylamino)phenyl]-17-hydroxy-21-methoxy-19-norpregna-4,9-diene-3,20-dione

télapristone — 11β-[4-(diméthylamino)phényl]-17-hydroxy-21-méthoxy-19-norprégna-4,9-diène-3,20-dione

telapristona — 11β-[4-(dimetilamino)fenil]-17-hidroxi-21-metoxi-19-norpregna-4,9-dieno-3,20-diona

$C_{29}H_{37}NO_4$



temanogrelum

temanogrel — 3-methoxy-*N*-{3-(1-methyl-1*H*-pyrazol-5-yl)-4-[2-(morpholin-4-yl)ethoxy]phenyl}benzamide

témanogrel — 3-méthoxy-*N*-{3-(1-méthyl-1*H*-pyrazol-5-yl)-4-[2-(morpholin-4-yl)éthoxy]phényl}benzamide

temanogrel — *N*-{3-(1-metil-1*H*-pirazol-5-il)-4-[2-(morfolin-4-il)etoxi]fenil}-3-metoxibenzamida

$C_{24}H_{28}N_4O_4$



tiprelestatum

tiprelestat — human elafin (elastase-specific inhibitor, skin-derived antileukoproteinase, peptidase inhibitor 3)

tiprélestat — élafine humaine (inhibiteur spécifique de l'élastase, antileukoprotéinase dérivé de la peau, inhibiteur 3 de peptidase)

tiprelestat — elafina humana (inhibidor específico de la elastasa, antileukoproteinasa derivada de la piel, inhibidor 3 de peptidasa)

$C_{254}H_{416}N_{72}O_{75}S_{10}$

```
AQEPVKGPVS  TKPGSCPIIL  IRCAMLNPPN  RCLKDTDCPG  IKKCCEGSCG  50
MACFVPQ                                                     57
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
16-45 23-49 32-44 38-53

tivantinibum

tivantinib — (3*R*,4*R*)-3-(5,6-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinolin-1-yl)-4-(1*H*-indol-3-yl)pyrrolidine-2,5-dione

tivantinib — (3*R*,4*R*)-3-(5,6-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinoléin-1-yl)-4-(1*H*-indol-3-yl)pyrrolidine-2,5-dione

tivantinib — (3*R*,4*R*)-3-(5,6-dihidro-4*H*-pirrolo[3,2,1-*ij*]quinolein-1-il)-4-(1*H*-indol-3-il)pirrolidina-2,5-diona

$C_{23}H_{19}N_3O_2$



tofogliflozinum

tofogliflozin — (1*S*,3'*R*,4'*S*,5'*S*,6'*R*)-6-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)-3',4',5',6'-tetrahydro-3*H*-spiro[2-benzofuran-1,2'-pyran]-3',4',5'-triol

tofogliflozine — (1*S*,3'*R*,4'*S*,5'*S*,6'*R*)-6-[(4-éthylphényl)méthyl]-6'-(hydroxyméthyl)-3',4',5',6'-tétrahydro-3*H*-spiro[2-benzofuran-1,2'-pyran]-3',4',5'-triol

tofogliflozina — (1*S*,3'*R*,4'*S*,5'*S*,6'*R*)-6-[(4-etilfenil)metil]-6'-(hidroximetil)-3',4',5',6'-tetrahidro-3*H*-espiro[2-benzofurano-1,2'-pirano]-3',4',5'-triol

$C_{22}H_{26}O_6$



trastuzumabum emtansinum #

trastuzumab emtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB2 (epidermal growth factor receptor 2, HER-2, p185c-erbB2, NEU, EGFR2)], humanized monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) - *Homo sapiens* IGHG1*03 (121-449) CH1 R120>K], (223-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01 (108'-214')]; (229-229":232-232")-bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(*N*-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker
For the *emtansine* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

trastuzumab emtansine

immunoglobuline G1-kappa, anti-[*Homo sapiens* ERBB2 (récepteur 2 du facteur de croissance épidermique, HER-2, p185c-erbB2, NEU, EGFR2)]], anticorps monoclonal humanisé conjugué au maytansinoïde DM1;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) - *Homo sapiens* IGHG1*03 (121-449) CH1 R120>K], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01 (108'-214')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker succinimidyl-4-(*N*-maléimidométhyl) cyclohexane-1-carboxylate (SMCC)
Pour la partie *emtasine*, veuillez vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

trastuzumab emtansina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ERBB2 (receptor 2 del factor de crecimiento epidérmico, HER-2, p185c-erbB2, NEU, EGFR2)]], anticuerpo monoclonal humanizado conjugado con maitansinoide DM1;
cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens* IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) - *Homo sapiens* IGHG1*03 (121-449) CH1 R120>K], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01 (108'-214')]; dimero (229-229":232-232")-bisdisulfuro; conjugado, en 3 a 4 residuos lisil por término medio, con el maitansinoide DM1 mediante un conector succinimidil-4-(*N*-maleimidometil) ciclohexano-1-carboxilato (SMCC)
Por la parte *emtansina*, por favor, vaya al documento *"INN for pharmaceutical substances: Names for radicals, groups & others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR  50
IYPTNGYTRY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG 100
GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS  50
ASFLYSGVPS RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    147-203    264-324    370-428
         22"-96"  147"-203"  264"-324"  370"-428"
Intra-L  23'-88'   134'-194'
         23'"-88'" 134'"-194'"
Inter-H-L  223-214'  223"-214'"
Inter-H-H  229-229"  232-232"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
300, 300"

ulimorelinum

ulimorelin

(2*R*,5*S*,8*R*,11*R*)-5-cyclopropyl-11-[(4-fluorophenyl)methyl]-2,7,8-trimethyl-2,3,4,5,7,8,10,11,13,14,15,16-dodecahydro-6*H*-1,4,7,10,13-benzoxatetraazacyclooctadecine-6,9,12-trione

ulimoréline

(2*R*,5*S*,8*R*,11*R*)-5-cyclopropyl-11-[(4-fluorophényl)méthyl]-2,7,8-triméthyl-2,3,4,5,7,8,10,11,13,14,15,16-dodécahydro-6*H*-1,4,7,10,13-benzoxatétraazacyclooctadécine-6,9,12-trione

ulimorelina

(2*R*,5*S*,8*R*,11*R*)-5-ciclopropil-11-[(4-fluorofenil)metil]-2,7,8-trimetil-2,3,4,5,7,8,10,11,13,14,15,16-dodecahidro-6*H*-1,4,7,10,13-benzoxatetraazaciclooctadecino-6,9,12(5*H*)-triona

$C_{30}H_{39}FN_4O_4$



umifenovirum

umifenovir — ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1*H*-indole-3-carboxylate

umifénovir — 6-bromo-4-[(diméthylamino)méthyl]-5-hydroxy-1-méthyl-2-[(phénylsulfanyl)méthyl]-1*H*-indole-3-carboxylate d'éthyle

umifenovir — 6-bromo-4-[(dimetilamino)metil]-5-hidroxi-1-metil-2-[(fenilsulfanil)metil]-1*H*-indol-3-carboxilato de etilo

$C_{22}H_{25}BrN_2O_3S$



umirolimusum

umirolimus — (3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-3-{(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-ethoxyethoxy)-3-méthoxycyclohexyl]-1-methylehyl}-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ª-octadecahydro-23,27-epoxy-5*H*-pyrido[2,1-*c*][1,4]oxazacyclohentriacontine-1,5,11,28,29(6*H*,31*H*)-pentone

umirolimus — (3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-3-{(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-ethoxyethoxy)-3-méthoxycyclohexyl]-1-methylehyl}-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ª-octadecahydro-23,27-epoxy-5*H*-pyrido[2,1-*c*][1,4]oxazacyclohentriacontine-1,5,11,28,29(6*H*,31*H*)-pentone

umirolimús — (3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-3-{(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-etoxietoxi)-3-metoxiciclohexil]-1-metiletil}-9,27-dihidroxi-10,21-dimetoxi-6,8,12,14,20,26-hexametil-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ª-octadecahidro-23,27-epoxi-5*H*-pirido[2,1-*c*][1,4]oxazaciclohentriacontina-1,5,11,28,29(6*H*,31*H*)-pentona

$C_{55}H_{87}NO_{14}$



uridini triacetas

uridine triacetate	2',3',5'-tri-*O*-acetyluridine
triacétate d'uridine	2',3',5'-tri-*O*-acétyluridine
triacetato de uridina	2',3',5'-tri-*O*-acetiluridina

$C_{15}H_{18}N_2O_9$



vaniprevirum

vaniprevir	(5*R*,7*S*,10*S*)-10-*tert*-butyl-*N*-{(1*R*,2*R*)-1-[*N*-(cyclopropanesulfonyl)carbamoyl]-2-ethylcyclopropyl}-15,15-dimethyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1*H*,3*H*,5*H*-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7-carboxamide
vaniprévir	(5*R*,7*S*,10*S*)-10-*tert*-butyl-*N*-{(1*R*,2*R*)-1-[*N*-(cyclopropanesulfonyl)carbamoyl]-2-éthylcyclopropyl}-15,15-diméthyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodécahydro-1*H*,3*H*,5*H*-2,23:5,8-diméthano-4,13,2,8,11-benzodioxatriazacyclohénicosine-7-carboxamide
vaniprevir	(5*R*,7*S*,10*S*)-10-*terc*-butil-*N*-{(1*R*,2*R*)-1-[*N*-(ciclopropanosulfonil)carbamoil]-2-etilciclopropil} -15,15-dimetil-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahidro-1*H*,3*H*,5*H*-2,23:5,8-dimetano-4,13,2,8,11-benzodioxatriazaciclohenicosina-7-carboxamida

$C_{38}H_{55}N_5O_9S$



vemurafenibum

vemurafenib	*N*-{3-[5-(4-chlorophenyl)-1*H*-pyrrolo[2,3-b]pyridin-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide
vémurafénib	*N*-{3-[5-(4-chlorophényl)-1*H*-pyrrolo[2,3-*b*]pyridin-3-carbonyl]-2,4-difluorophényl}propane-1-sulfonamide
vemurafenib	*N*-{3-[5-(4-clorofenil)-1*H*-pirrolo[2,3-*b*]piridin-3-carbonil]-2,4-difluorofenil}propano-1-sulfonamida

$C_{23}H_{18}ClF_2N_3O_3S$



verubulinum

verubulin	*N*-(4-methoxyphenyl)-*N*,2-dimethylquinazolin-4-amine
vérubuline	*N*-(4-méthoxyphényl)-*N*,2-diméthylquinazolin-4-amine
verubulina	*N*,2-dimetil-*N*-(4-metoxifenil)quinazolin-4-amina

$C_{17}H_{17}N_3O$



vidofludimusum

vidofludimus — 2-[*N*-(3-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl)carbamoyl]cyclopent-1-ene-1-carboxylic acid

vidofludimus — acide 2-[*N*-(3-fluoro-3'-méthoxy[1,1'-biphényl]-4-yl)carbamoyl]cyclopent-1-ène-1-carboxylique

vidofludimús — ácido 2-[*N*-(3-fluoro-3'-metoxi[1,1'-bifenil]-4-il)carbamoil]ciclopent-1-eno-1-carboxílico

$C_{20}H_{18}FNO_4$



vilanterolum

vilanterol — 4-{(1*R*)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol

vilantérol — 4-{(1*R*)-2-[(6-{2-[(2,6-dichlorophényl)méthoxy]éthoxy}hexyl)amino]-1-hydroxyéthyl}-2-(hydroxyméthyl)phénol

vilanterol — 4-{(1*R*)-2-[(6-{2-[(2,6-diclorofenil)metoxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol

$C_{24}H_{33}Cl_2NO_5$



vipadenantum

vipadenant — 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-5-amine

vipadénant — 3-[(4-amino-3-méthylphényl)méthyl]-7-(furan-2-yl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-5-amine

vipadenant — 3-[(4-amino-3-metilfenil)metil]-7-(furan-2-il)-3*H*-[1,2,3]triazolo[4,5-*d*]pirimidin-5-amina

$C_{16}H_{15}N_7O$



vismodegibum

vismodegib	2-chloro-*N*-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methanesulfonyl)benzamide
vismodégib	2-chloro-*N*-[4-chloro-3-(pyridin-2-yl)phényl]-4-(méthylsulfonyl)benzamide
vismodegib	2-cloro-*N*-[4-cloro-3-(piridin-2-il)fenil]-4-(metanosulfonil)benzamida

$C_{19}H_{14}Cl_2N_2O_3S$



vorapaxarum

vorapaxar	ethyl [(1*R*,3a*R*,4a*R*,6*R*,8a*R*,9*S*,9a*S*)-9-{(1*E*)-2-[5-(3-fluorophenyl)pyridine-2-yl]ethen-1-yl}-1-methyl-3-oxododecahydronaphtho[2,3-*c*]furan-6-yl]carbamate
vorapaxar	[(1*R*,3a*R*,4a*R*,6*R*,8a*R*,9*S*,9a*S*)-9-{(1*E*)-2-[5-(3-fluorophényl)pyridin-2-yl]éthén-1-yl}-1-méthyl-3-oxododécahydronaphto[2,3-*c*]furan-6-yl]carbamate d'éthyle
vorapaxar	[(1*R*,3a*R*,4a*R*,6*R*,8a*R*,9*S*,9a*S*)-9-{(1*E*)-2-[5-(3-fluorofenil)piridin-2-il]eten-1-il}-1-metil-3-oxododecahidronafto[2,3-*c*]furan-6-il]carbamato de etilo

$C_{29}H_{33}FN_2O_4$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Non Proprietary Names (Rec. INN): List 6
(WHO Chronicle, Vol. 20, No. 11, 1966)

	dalanatum insulinum	
p. 424	dalanated insulin	*replace the description by the following*
		an insulin derivative prepared by the removal of the *C*-terminal alanine from the B chain of insulin

Recommended International Non Proprietary Names (Rec. INN): List 31
Denominations communes internationales recommandées (DCI Rec.): Liste 31
Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 31
(WHO Drug Information, Vol. 5, No. 3, 1991)

p. 13	*delete/supprimer/suprimáse*	*insert/insérer/insertese*
	suplatastum tosilas	**suplatasti tosilas**

Recommended International Non Proprietary Names (Rec. INN): List 51
Denominations communes internationales recommandées (DCI Rec.): Liste 51
Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 51
(WHO Drug Information, Vol. 18, No. 1, 2004)

p. 102	*delete/supprimer/suprimáse*	*insert/insérer/insertese*
	ralfinamidum	**priralfinamidum**
	ralfinamide	priralfinamide
	ralfinamide	priralfinamide
	ralfinamida	priralfinamida

Recommended International Non Proprietary Names (Rec. INN): List 59
Denominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)

p. 66	*delete/supprimer/suprimáse*	*insert/insérer/insertese*
	sergliflozinum etabonas	**sergliflozini etabonas**

Recommended International Non Proprietary Names (Rec. INN): List 63
Denominations communes internationales recommandées (DCI Rec.): Liste 63
Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)

p. 56	**fonturacetamum**	
	fonturacetam	*replace the chemical name by the following*
	fonturacétam	*remplacer le nom chimique par le suivant*
	fonturacetam	*sustitúyase el nombre químico por el siguiente*
		rac-2-(2-oxo-4-phenylpyrolidin-1-yl)acetamide
		rac-2-(2-oxo-4-phénylpyrolidin-1-yl)acétamide
		rac-2-(4-fenil-2-oxopirolidin-1-il)acetamida

p. 74 **sifalimumabum**

sifalimumab	*replace the description by the following*
sifalimumab	*remplacer la description par la suivante*
sifalimumab	*sustitúyase la descripción por la siguiente*

immunoglobulin G1-kappa, anti-[*Homo sapiens* interferon alpha (IFN-alpha)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV1-18*01 (95.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) –IGHG1*03 CH1 R120>K (213) (117-446)], (219-213')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) –IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (225-225'':228-228'')-bisdisulfide dimer

immunoglobuline G1-kappa, anti-[*Homo sapiens* interféron alpha (IFN-alpha)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV1-18*01 (95.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) –IGHG1*03 CH1 R120>K (213) (117-446)], (219-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) –IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (225-225'':228-228'')-bisdisulfure

inmunoglobulina G1-kappa, anti-[interferón alfa (IFN-alfa) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV1-18*01 (95.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) –IGHG1*03 CH1 R120>K (213) (117-446)], (219-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) –IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (225-225'':228-228'')-bisdisulfuro

Recommended International Non Proprietary Names (Rec. INN): List 64
Denominations communes internationales recommandées (DCI Rec.): Liste 64
Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 64
(WHO Drug Information, Vol. 24, No. 3, 2010)

p. 260 **afatinibum**

afatinib	*replace the chemical name by the following*
afatinib	*remplacer le nom chimique par le suivant*
afatinib	*sustitúyase el nombre químico por el siguiente*

(2*E*)-*N*-[4-(3-chloro-4-fluoroanilino)-7-{[(3*S*)-oxolan-3-yl]oxy}quinazolin-6-yl]-4-(dimethylamino)but-2-enamide

(2*E*)-*N*-[4-(3-chloro-4-fluoroanilino]-7-{[(3*S*)-oxolan-3-yl]oxy}quinazolin-6-y]-4-(diméthylamino)but-2-énamide

(2*E*)-*N*-[4-(3-cloro-4-fluoroanilino)-7-{[(3*S*)-oxolan-3-il]oxi}quinazolin-6-il]-4-(dimetilamino)but-2-enamida

p. 279 **sotaterceptum**

sotatercept	*replace the description by the following*
sotatercept	*remplacer la descriptions par la suivante*
sotatercept	*sustitúyase la descripción por la siguiente*

fusion protein for immune applications (FPIA) comprising *Homo sapiens* ACVR2A (activin receptor type 2A, activin receptor type IIA) fragment fused with *Homo sapiens* immunoglobulin G1 Fc fragment;
Homo sapiens ACVR2A, 21-135 precursor fragment (1-115) -threonyl-triglycyl linker (116-119) -gamma1 chain H-CH2-CH3 fragment (120-344) [*Homo sapiens* IGHG1*03 hinge (120-127), CH2, A115>V (227) (128-237), CH3 (238-344)]; (123-123':126-126')-bisdisulfide dimer

protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d'*Homo sapiens* ACVR2A (récepteur type 2A de l'activine, récepteur type IIA de l'activine) fusionné au fragment Fc de l'*Homo sapiens* immunoglobuline G1;
fragment précurseur 21-135 de *Homo sapiens* ACVR2A (1-115) -linker thréonyl-triglycyl (116-119) -fragment H-CH2-CH3 de chaîne gamma1 (120-344) [*Homo sapiens* IGHG1*03 charnière (120-127), CH2, A115>V (227) (128-237), CH3 (238-344)]; dimère (123-123':126-126')-bisdisulfure

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de ACVR2A (receptor tipo 2A de la activina, receptor tipo IIA de la activina) de *Homo sapiens* fusionado al fragmento Fc de la inmunoglobulina G1 de *Homo sapiens*;
fragmento precursor 21-135 de ACVR2A de *Homo sapiens* (1-115)-conector treonil-triglicil (116-119) -fragmento H-CH2-CH3 de cadena gamma1 (120-344) [*Homo sapiens* IGHG1*03 bisagra(120-127), CH2, A115>V (128-237), CH3 (238-344)]; dímero (123-123':126-126')-bisdisulfuro

Electronic structure available on Mednet: http://mednet.who.int/
Structure electronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/

* *"INN for pharmaceutical substances: Names for radicals, groups & others"* document available at / document disponible à / documento disponible en :
http://www.who.int/medicines/services/inn/publication/en/index.html

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.